Join us for our two part Science Series, designed specifically for in-house lawyers working within life sciences companies. This unique programme aims to bridge the gap between legal expertise and scientific innovation, providing lawyers with user-friendly overview of the science underlying some cutting-edge technologies.

Each session will give an overview of the science and explanation of the jargon, followed by related legal considerations. Aimed at those who would like to deepen their understanding of the scientific principles driving their company's technological advancements - whether you are new to the field or looking to refresh your knowledge.

Antibody-drug conjugates (ADCs) are revolutionising targeted therapy, particular for cancer, by harnessing the specificity of antibodies to deliver drugs directly to target cells. There is also currently a lot of attention on radiopharmaceuticals, which pair radioactive particles with antibodies or other targeted carrier molecules, and have uses in diagnostic imaging as well as therapeutics.

In this session, Bristows will explore the science behind ADCs and radiopharmaceuticals, and examine the legal considerations relevant to these technologies.